Katharine Peterson - 14 May 2025 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Accounting Officer
Signature
/s/ Eric Devroe, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
14 May 2025
Net transactions value
-$113
Form type
4
Filing time
16 May 2025, 16:21:13 UTC
Previous filing
04 Mar 2025
Next filing
18 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Peterson Katharine Chief Accounting Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Eric Devroe, Attorney-in-Fact 16 May 2025 0002022214

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $113 -99 -2.2% $1.14 4,320 14 May 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.